AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
Feb 5 () - CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost ...
Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...
Investor's Business Daily on MSN
AbbVie pummeled after delivering a fourth-quarter beat — on the back of Humira
Investors pummeled AbbVie stock Wednesday after the company delivered a fourth-quarter sales beat, thanks to Humira.
AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.
CVS Health® today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...
Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...
AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.
Abbvie () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools for ...
Elevating CMS oversight operationalizes Any Willing Provider by mandating “reasonable and relevant” participation terms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results